Veterinary Infectious Disease Diagnostics Market

Veterinary Infectious Disease Diagnostics Market Analysis

The veterinary infectious disease diagnostics market is valued at USD 2.30 billion in 2025 and is forecast to reach USD 3.46 billion by 2030, advancing at an 8.51% CAGR. Growth stems from rapid adoption of AI-enabled diagnostic platforms, expanding companion-animal populations, and stricter One Health regulations that compel antimicrobial-resistance (AMR) surveillance. Molecular techniques such as PCR and next-generation sequencing are steadily replacing traditional immunoassays because they deliver higher sensitivity and faster turnaround, while cartridge-based point-of-care (POC) tests are reshaping daily clinical workflows. Vendors are differentiating through integrated ecosystems that combine AI image analysis, cloud data management, and reference-laboratory networks, allowing clinics to offer same-visit diagnoses that improve therapeutic outcomes and client satisfaction. Headwinds include rising veterinary-care costs and a widening veterinarian workforce gap, both of which may limit diagnostic uptake in price-sensitive segments and rural geographies.

Global Veterinary Infectious Disease Diagnostics Market Trends and Insights

AI-Powered Image Analysis Adoption In Vet Labs

AI integration is moving laboratory interpretation from subjective, manual review to data-driven automation. Platforms such as Zoetis’ Vetscan Imagyst now screen lymph-node and skin-mass aspirates in minutes, a process that previously required days at external labs, enabling faster treatment decisions and improving client adherence. Nearly 30% of U.S. veterinarians already apply AI for imaging or record management tasks. Regulatory bodies, however, insist on rigorous validation before broad clinical use, promoting collaborative studies that benchmark AI accuracy against board-certified radiologists. Early adopters report sharper diagnostic confidence, a crucial benefit given the looming shortage of skilled practitioners. As reimbursements remain procedure-driven, AI tools that speed results without compromising quality are expected to shift from competitive advantage to baseline requirement, fuelling demand across the veterinary infectious disease diagnostics market.

Advanced Diagnostic Devices For Animals

Multiplex PCR and cartridge-based POC systems are compressing test windows from days to minutes, helping clinics avoid follow-up visits and reduce antibiotic misuse. A 2025 triplex real-time PCR assay for swine respiratory diseases achieved 100% agreement with national standards, underlining molecular reliability. Zoetis’ Vetscan OptiCell extends this efficiency to complete blood counts in less than 10 minutes, offering reference-lab precision in-clinic^{[1]Zoetis, “Zoetis to Preview AI-Powered Cytologic Analysis Technology at VMX,” zoetisus.com}. Genomic selection tools embedded within herd-health programs reduce disease susceptibility and antibiotic dependency, directly tying diagnostics to improved production metrics. Clinics that invest in such devices report higher client retention and the ability to charge premium service fees, reinforcing capital-investment cycles that sustain the veterinary infectious disease diagnostics market.

Increasing Companion Animal Population

U.S. households hosted 89.7 million dogs and 73.8 million cats in 2024, up 45%. Similar growth trajectories in China and India are boosting first-time vet visits for vaccinations and baseline health screens. Yet average U.S. veterinary spending fell 4% in the same period, proving that larger pet populations do not guarantee revenue if price sensitivity rises. Diagnostics firms therefore segment offerings into core and premium panels, ensuring essential coverage at competitive price points while upselling genomic or AI-enhanced tests to affluent owners. Population density in megacities also elevates zoonotic-disease risk, heightening demand for rapid communicable-disease screening and sustaining momentum in the veterinary infectious disease diagnostics market.

One-Health AMR Surveillance Regulations

The World Organisation for Animal Health warns that AMR could slash USD 575 billion from global GDP by 2050 if unchecked^{[2]World Organisation for Animal Health, “Forecasting the Fallout from AMR,” woah.org}. Governments are mandating genomic surveillance of livestock pathogens and harmonized data exchange with human-health agencies. Real-time sequencing is now embedded in outbreak response protocols, driving laboratories to acquire high-throughput sequencers and bioinformatics pipelines. Vendors that bundle instruments, reagents, and cloud analytics into turnkey AMR-monitoring suites gain a compliance-driven market entry route. Developing regions are racing to upgrade lab capacity, creating multi-year revenue streams for diagnostic suppliers that provide training and maintenance services alongside tests, thereby enlarging the veterinary infectious disease diagnostics market.

Shortage Of Skilled Veterinarians

The United States alone is projected to lack 70,092 veterinarians by 2032, with only 52,926 graduates expected, a gap driven by rural attrition and lifestyle preferences^{[3]American Association of Veterinary Medical Colleges, “Demand for and Supply of Veterinarians in the U.S. to 2032,” aavmc.org}. Large-animal practice is hardest hit; livestock-focused vets have declined 90% since World War II, now representing under 2% of the profession. Fewer clinicians limit test ordering, especially in remote areas where mobile labs or tele-diagnostics must compensate. Technology that automates sample collection or streamlines interpretation partly offsets manpower gaps, but sustained shortages weigh on long-term volumes and slow expansion of the veterinary infectious disease diagnostics market.

High Pet-Care Costs

Veterinary fees are rising faster than general inflation across Europe and North America, with routine procedures such as pyometra surgery posting the steepest increases. Average U.S. household spending slid to USD 580 for dogs and USD 433 for cats in 2024, reflecting cost-averse behaviour. Owners often defer comprehensive panels in favour of minimal tests, pressuring clinics to offer tiered pricing or wellness plans. POC devices that reduce follow-up visits help ease total episode cost, but capital investment is hard to justify for low-volume practices. This price sensitivity tempers revenue growth, especially for emerging-market clinics, and curbs overall momentum in the veterinary infectious disease diagnostics market.

Segment Analysis

By Technology: Molecular Diagnostics Drive Innovation Despite Immunodiagnostics Dominance

Immunodiagnostics retained a 44.35% revenue share in 2024 due to entrenched ELISA and chemiluminescent assays across routine screening. Nevertheless, molecular diagnostics recorded the quickest gains and are forecast to post a 10.25% CAGR, mirroring the broader shift toward precision medicine. Clinics adopting multiplex PCR report fewer inconclusive results and lower antibiotic misuse, boosting client confidence and strengthening loyalty within the veterinary infectious disease diagnostics market. Cartridges that integrate extraction and amplification simplify workflows, allowing smaller practices to perform formerly complex assays. Vendors further add AI-driven result interpretation, reducing error rates and training demands. Over the forecast window, integrated workstations that merge serology, PCR, and hematology functionalities are expected to dominate new-equipment purchases, underscoring the sector’s convergence trend.

Market momentum also stems from next-generation sequencing (NGS) rollouts that enable pathogen discovery and AMR gene tracking. While cost per sample remains high, pooled testing strategies in herd health make NGS economically viable for high-value livestock operations. Cloud-based bioinformatics reduces on-premise infrastructure needs, fostering adoption across resource-constrained geographies. Immunodiagnostics will persist for high-throughput surveillance and cost-sensitive settings; however, their share is projected to decline gradually as rapid molecular platforms become ubiquitous across the veterinary infectious disease diagnostics market.

By Animal Type: Food-Producing Animals Accelerate Growth Through Regulatory Compliance

Companion animals generated 57.53% of global revenue in 2024, anchored by rising pet humanization and insurance uptake. Yet food-producing animals will expand fastest at 11.85% CAGR to 2030 as regulators impose stringent monitoring after incidents such as the H5N1 dairy-cattle outbreak that affected 989 U.S. herds. Livestock producers increasingly embed diagnostics in herd-health protocols to avoid culling losses and export bans. Governments subsidize surveillance kits, narrowing cost barriers and enlarging install bases for barn-side PCR readers, which, in turn, fuel the veterinary infectious disease diagnostics market size for this segment.

Genomic selection augments diagnostics by identifying disease-resistance alleles, reducing long-term medication costs and residue risks. Integrated platforms that merge pathogen detection with genetic profiling help producers comply with AMR-reporting mandates and sustainability certifications. Companion-animal growth will continue, albeit at a lower rate, as economic pressures spur selective testing behaviour. Clinics that offer bundled vaccination-plus-diagnostic packages should preserve volumes even in cost-sensitive markets, sustaining their position within the veterinary infectious disease diagnostics market.

By Infection Type: Viral Diagnostics Gain Momentum Through Outbreak Response

Bacterial diseases represented 35.82% of 2024 revenue because established protocols and high incidence keep test volumes stable. The viral segment, however, is poised for the highest 9.31% CAGR as global trade, migration, and climate change heighten outbreak frequency. The H5N1 episode underscored the need for rapid multi-species viral panels capable of detecting emergent strains. Labs investing in high-throughput PCR and sequencing can pivot quickly during crises, generating surges in consumable demand and driving incremental growth across the veterinary infectious disease diagnostics market.

Parasitic and fungal pathogens still represent niche but rising sub-segments thanks to improved screening accuracy. Antech’s advanced parasite panel detects low-abundance infections that were often missed previously, enabling early intervention and reducing zoonotic risk. Holistic panels covering bacterial, viral, and parasitic targets on the same cartridge are emerging, lowering per-sample costs and simplifying inventory, thereby enhancing value for mixed-practice clinics.

By End User: Point-of-Care Testing Transforms Practice Workflows

Reference laboratories controlled 45.63% of global sales in 2024, leveraging their breadth of assays and quality-control rigor. Yet POC and in-house testing will outpace all other segments at 10.25% CAGR because immediate results eliminate return visits and boost treatment compliance. Platforms such as Vetscan Imagyst provide on-site cytology that historically required external review, shortening time to diagnosis from two days to under 10 minutes. For emergencies, same-visit diagnostics directly influence survival rates and client satisfaction, reinforcing uptake across the veterinary infectious disease diagnostics market.

Research institutes and universities remain innovation engines, validating assays and training veterinarians in advanced techniques. Collaboration with commercial vendors accelerates technology transfer, with spin-outs often targeting specialised niches such as exotic-animal diagnostics or wildlife disease surveillance. Over the forecast period, hybrid models that link POC devices to central lab networks via cloud reporting will offer the best of both worlds—fast preliminary insights backed by reference-level confirmation—bolstering confidence in POC adoption.

Geography Analysis

North America led the veterinary infectious disease diagnostics market in 2024 with 40.63% share due to mature veterinary infrastructure, high pet-insurance penetration, and robust livestock surveillance funding. Federal H5N1 mitigation programs drive continual demand for avian and bovine panels, sustaining consumable sales. Europe follows closely, characterised by stringent welfare rules and near-universal canine insurance in nations like Sweden, which support comprehensive diagnostic uptake. Pan-EU AMR directives also bolster molecular and genomic test adoption.

Asia-Pacific stands out with the quickest 9.27% CAGR, fuelled by rising disposable incomes and rapid urbanisation in China, India, and Southeast Asia. Government-backed livestock modernisation programs require continuous pathogen monitoring, while middle-class pet owners increasingly demand Western-style preventive care, expanding the veterinary infectious disease diagnostics market. Partnerships with local distributors and price-tiered product lines are essential for penetration, given heterogeneous regulatory regimes and price sensitivity. Latin America, the Middle East, and Africa offer incremental growth via livestock disease-control initiatives and rising companion-animal ownership, but infrastructure limitations necessitate mobile-lab or satellite-network models to unlock full potential.

Competitive Landscape

The veterinary infectious disease diagnostics market is moderately fragmented. IDEXX, Zoetis, and Thermo Fisher Scientific leverage economy-of-scale R&D budgets and global distribution to maintain leadership. IDEXX broadened its Catalyst test menu in 2025 to include pancreatitis markers, offering quantitative results in under 10 minutes and seamless VetConnect PLUS integration. Zoetis deepened vertical integration by opening a 32,000-square-foot Louisville reference lab co-located with UPS Healthcare, ensuring overnight specimen logistics and enhanced customer retention. Thermo Fisher extends reach through OEM agreements that bundle reagents with existing automated platforms in mixed-practice clinics.

Emerging firms concentrate on AI algorithms, species-specific panels, and cost-efficient POC devices, often partnering with academic labs for validation. Mergers and acquisitions are expected as top players seek proprietary AI models or geographic expansion, compressing development timelines. Competitive advantage now hinges on ecosystem breadth—hardware, consumables, software, and analytics—rather than standalone assays. Companies that deliver subscription-based reagent replenishment plus cloud analytical upgrades are positioned to lock in recurring revenue across the veterinary infectious disease diagnostics market.